V CompBrief BY VELARION

Chief Financial Officer · 4D Molecular Therapeutics, Inc. (FDMT)

Kristian Humer

FY2025 is the first fiscal year CompBrief holds for Kristian Humer as a named executive officer of 4D Molecular Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$3,990,903

1st of 3 named executive officers at 4D Molecular Therapeutics by FY2025 total.

3 named officers on file for 4D Molecular Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. 4D Molecular Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how 4D Molecular Therapeutics’s whole pay program stands against its peers

  • 4D Molecular Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FDMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Free

Get Kristian Humer’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Kristian Humer and every company like it: Velarion Intel, free for 3 days, no card →

Kristian Humer compensation by year

4D Molecular Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as 4D Molecular Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$66,000
Bonus$50,000
Stock awards$0
Option awards$3,874,656
Non-equity incentive$0
Pension and deferred compensation$0
All other$247
Total$3,990,903

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017427, and prior-year filings. Open the filing on EDGAR.

How this page was built: the 4D Molecular Therapeutics, Inc. filed document, accession 0001140361-26-017427. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option480,000—$10.51

Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

4D Molecular Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Kristian Humer · this pageChief Financial Officer$3,990,903
David KirnPresident and Chief Executive Officer$2,051,343
Fariborz KamalFormer Chief Operating Officer & President$1,441,573

Kristian Humer's compensation dossier, 4D Molecular Therapeutics

You have read Kristian Humer's totals and holdings. The dossier adds each equity grant 4D Molecular Therapeutics disclosed for Kristian Humer and 4D Molecular Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full 4D Molecular Therapeutics compensation record

free company brief
4D Molecular Therapeutics, Inc. (FDMT) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order 4D Molecular Therapeutics's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order FDMT

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Kristian Humer's compensation dossier